Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them

The pharmaceutical and biotechnology industries seem to be stepping up their attempts to secure a carve-out for biopharmaceutical patents from the IPR process. Last week, Jim Greenwood, the president and CEO of BIO and John Castellani, the president…

Get unlimited access to all IAM content